DESFERAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Desferal, and what generic alternatives are available?
Desferal is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in DESFERAL is deferoxamine mesylate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the deferoxamine mesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Desferal
A generic version of DESFERAL was approved as deferoxamine mesylate by HOSPIRA on March 17th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DESFERAL?
- What are the global sales for DESFERAL?
- What is Average Wholesale Price for DESFERAL?
Summary for DESFERAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 136 |
| Clinical Trials: | 20 |
| Patent Applications: | 4,512 |
| Drug Prices: | Drug price information for DESFERAL |
| What excipients (inactive ingredients) are in DESFERAL? | DESFERAL excipients list |
| DailyMed Link: | DESFERAL at DailyMed |
Recent Clinical Trials for DESFERAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Aditya S. Pandey, MD | Phase 2 |
| Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research | Phase 2 |
| Abderrahmane Mami Hospital | Phase 3 |
Pharmacology for DESFERAL
| Drug Class | Iron Chelator |
| Mechanism of Action | Iron Chelating Activity |
US Patents and Regulatory Information for DESFERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-002 | May 25, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DESFERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | DESFERAL | deferoxamine mesylate | INJECTABLE;INJECTION | 016267-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
